SCHEMBL660403

SCHEMBL660403

CC(C)(C)OC(=O)N1CCN(c2ccc(N)cc2F)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.53
MAPT P10636 5/20 0.51
ALDH1A1 P00352 3/20 0.51
LMNA P02545 3/20 0.51
MAPK1 P28482 2/20 0.51
GFER P55789 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
SMARCA2 P51531 1/20 0.50
SMARCA4 P51532 1/20 0.50
PBRM1 Q86U86 1/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SLC6A9 P48067 1/20 0.47
GPR55 Q9Y2T6 1/20 0.47
NPC1 O15118 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29508938 1.00 NR1H2 (0.53) NR1H2MAPTALDH1A1LMNAMAPK1
SCHEMBL13419696 0.95 NR1H2 (0.49) NR1H2MAPTALDH1A1LMNAMAPK1
SCHEMBL31639561 0.95 NR1H2 (0.49) NR1H2MAPTALDH1A1LMNAMAPK1
SCHEMBL30998086 0.90 NR1H2 (0.53) NR1H2MAPTALDH1A1LMNAL3MBTL1
SCHEMBL1613019 0.90 NR1H2 (0.53) NR1H2MAPTALDH1A1LMNAL3MBTL1
SCHEMBL23783164 0.89 GPR119 (0.58) NR1H2GPR119SMN1; SMN2
SCHEMBL31333261 0.89 HRH3 (0.51) NR1H2MAPTALDH1A1LMNAMAPK1
SCHEMBL24351663 0.89 HRH3 (0.51) NR1H2ALDH1A1GPR119TP53THRB
SCHEMBL25366909 0.87 NR1H2 (0.46) NR1H2MAPTALDH1A1LMNAMAPK1
SCHEMBL31334472 0.87 GPR119 (0.57) NR1H2GPR119SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117820239-A Novel CSF1R inhibitor and preparation method and application thereof 四川大学华西医院 2024-04-05 CN claimed
CN-113651799-A Six-membered non-aromatic ring-containing diaryl pyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof 山东大学 2021-11-16 CN claimed
WO-2005051933-A1 AN IMPROVED PROCESS FOR THE SYNTHESIS OF 4-(4-BENZYLOXY-CARBONYLAMINO-2-FLUOROPHENYL)-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER, A KEY INTERMEDIATE FOR OXAZOLIDINONE ANTIMICROBIALS AND COMPOUNDS PREPARED THEREBY RANBAXY LABORATORIES LIMITED (IN) 2005-06-09 WO claimed
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 EP disclosed
US-12559492-B2 BRAF degraders C4 THERAPEUTICS, INC. (US) 2026-02-24 US disclosed
US-20260007681-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS UNIV MICHIGAN (US) 2026-01-08 US disclosed
US-20260000676-A1 CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS UNIV MICHIGAN REGENTS (US) 2026-01-01 US disclosed
US-20250367193-A1 BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY NIKANG THERAPEUTICS INC (DE) 2025-12-04 US disclosed
US-12486253-B2 Therapeutics for the degradation of mutant BRAF C4 THERAPEUTICS, INC. (US) 2025-12-02 US disclosed
EP-4652161-A1 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS Uppthera, Inc. (KR) 2025-11-26 EP disclosed
EP-4640686-A1 DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Innocure Therapeutics, Inc. (KR) 2025-10-29 EP disclosed
US-20050070526-A1 Novel antibacterial agents ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2005-03-31 US disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed
WO-2004018439-A1 NOVEL ANTIBACTERIAL AGENTS ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) 2004-03-04 WO disclosed
EP-0640077-B1 OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS UPJOHN CO (US) 2002-06-26 EP disclosed
CN-1044236-C Oxazolidinone antimicrobials containing substituted diazine moieties PHARMACIA UPJOHN CO (US) 1999-07-21 CN disclosed
US-5700799-A MICROBIOCIDES FOR TREATING HUMAN OR ANIMAL DISEASES PHARMACIA & UPJOHN COMPANY (US) 1997-12-23 US disclosed
US-5547950-A FOR TREATING DRUG RESISTANT STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS THE UPJOHN COMPANY (US) 1996-08-20 US disclosed
WO-1993023384-A1 OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS THE UPJOHN COMPANY (US) 1993-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559492-B2 BRAF degraders BRAF, NRAS, HRAS NR1H2 473/4885MAPT 4613/4885ALDH1A1 2764/4885
US-12486253-B2 Therapeutics for the degradation of mutant BRAF BRAF, NRAS, KRAS NR1H2 3983/4885MAPT 1093/4885ALDH1A1 1471/4885
US-20050070526-A1 Novel antibacterial agents TBCD, OXA1L, ALPI NR1H2 1086/4885MAPT 48/4885ALDH1A1 2001/4885
US-20250367193-A1 BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY CDK2, SKP2, CCNK NR1H2 2908/4885MAPT 2877/4885ALDH1A1 3087/4885
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists ADORA2A, ADORA3, ADORA1 NR1H2 1405/4885MAPT 2814/4885ALDH1A1 591/4885
US-20260000676-A1 CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, ESRRB NR1H2 50/4885MAPT 4644/4885ALDH1A1 633/4885
US-20260007681-A1 INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ESRRA, ESR2, AR NR1H2 105/4885MAPT 4310/4885ALDH1A1 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.